TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Citius Oncology ( (CTOR) ) has shared an announcement.
On October 23, 2025, Citius Oncology announced its readiness to launch LYMPHIR in Q4 2025, having invested approximately $90 million in its development and pre-commercial efforts. The company has completed significant pre-commercial activities, including manufacturing inventory, securing supply chain agreements, and developing a marketing strategy. The launch is expected to impact the estimated $400 million addressable U.S. market for CTCL therapies, positioning Citius Oncology as a key player in this niche market.
The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.
Spark’s Take on CTOR Stock
According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.
Citius Oncology’s stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.
To see Spark’s full report on CTOR stock, click here.
More about Citius Oncology
Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its lead product, LYMPHIR, is FDA-approved for treating adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The company is publicly traded on NASDAQ under the ticker CTOR and is a majority-owned subsidiary of Citius Pharmaceuticals, Inc.
Average Trading Volume: 342,824
Technical Sentiment Signal: Sell
Current Market Cap: $149.5M
For a thorough assessment of CTOR stock, go to TipRanks’ Stock Analysis page.